** Shares of cancer drug developer Tempest Therapeutics TPST.O rise ~9% to $7.79 in extended trading
** TPST says it is exploring strategic alternatives, such as mergers or partnerships, to advance its cancer treatment programs
** Company's pipeline includes its lead liver cancer drug, amezalpat, and TPST-1495, a treatment for familial adenomatous polyposis, a rare genetic disorder
** Amezalpat received both Orphan Drug and Fast Track designations from the US FDA
** As of last close, stock down 34% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。